Cellular Senescence in Liver Disease and Regeneration

Sofia Ferreira-Gonzalez, PhD1  Daniel Rodrigo-Torres, PhD1  Victoria L. Gadd, PhD1  Stuart J. Forbes, MBChB, PhD, FRCP(Ed), FRSE, FMedSci1

1MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom

Semin Liver Dis 2021;41:50–66.

Abstract

Cellular senescence is an irreversible cell cycle arrest implemented by the cell as a result of stressful insults. Characterized by phenotypic alterations, including secretome changes and genomic instability, senescence is capable of exerting both detrimental and beneficial processes. Accumulating evidence has shown that cellular senescence plays a relevant role in the occurrence and development of liver disease, as a mechanism to contain damage and promote regeneration, but also characterizing the onset and correlating with the extent of damage. The evidence of senescent mechanisms acting on the cell populations of the liver will be described including the role of markers to detect cellular senescence. Overall, this review intends to summarize the role of senescence in liver homeostasis, injury, disease, and regeneration.

Keywords

► senescence  ► liver disease  ► liver regeneration

We are living longer than at any point time in human history.1 Life expectancy has increased in the developed world from an average 40.2 years in 1891 to 82.8 years in 2018 (for females in United Kingdom2).

At the beginning of the 20th century, the epidemiological transition that led to more than a doubling in the average lifespan sparked the idea that ever-increasing age and near immortality could be reached if the human being was provided with appropriate nutrition and correct health interventions (e.g., child immunization).3

It was in this context, in an era of rapid change, when the controversial Nobel Prize laureate and eugenicist Alexis Carrel propelled this idea of immortality.4 In his experiments, Carrel, who was attempting to preserve life outside the body, claimed to have maintained cells from chick heart embryos alive and dividing from 1912 to 1946.5,6 The implicit idea of these studies was that by understanding cellular mechanisms, the secrets of an organism’s immortality could be revealed.7

This concept was challenged when Hayflick and Moorhead described that human cells in culture showed a limited proliferative capacity and entered cellular senescence.8 Hayflick and Moorhead observed how the cells adapted to the culture conditions and began to proliferate but, after certain number of divisions, they invariably changed their morphology, remaining metabolically active but unable to divide again (despite the presence of growth factors in the medium).8

Hayflick termed this phenomenon cellular senescence, and despite the initial reluctance of his colleagues to accept that primary cell cultures were mortal,9 subsequent publications helped define a new phenotype, the function of which continues to be unraveled.

Cellular Senescence in Homeostasis and Disease

Our cells and tissues are constantly exposed to injury, including the liver, subjected to injury due to its role in toxin metabolism and susceptibility to infections.9

In response to a variety of stresses, cells either undergo apoptosis (a form of programed death) or senescence.10 Although each mechanism has its own advantages, in a context where a cell becomes mutated, senescence protects the integrity of the tissue by preventing proliferation of these cells and the transmission of destructive alterations to the next generation that may give rise to further injury or cancer.11

Senescence is therefore considered a preventive mechanism against tumor formation. This is supported by the fact that tumorigenesis selects cells that can bypass senescence12,13 and that alterations of key effectors of senescence, such as p53, are common in tumors.14

When one of these cells acquires a senescent phenotype, it is no longer able to proliferate, but remains metabolically

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited (https://creativecommons.org/licenses/by/4.0/).
active and is able to communicate with the surrounding environment. To do so, senescent cells secrete a myriad of factors that act in an autocrine and paracrine manner to reinforce senescence, communicate its compromised status to the rest of the tissue, and to activate immune surveillance to promote clearance of the damaged area and induce regeneration. It is therefore an essential mechanism activated during tissue damage, wound healing, tissue plasticity, and regeneration. In line with this protective role, senescence can be activated in postmitotic nonmalignant cells that if uncontrolled could aggravate certain pathologies. For example, cellular senescence of scar-forming cells attenuates fibrosis in the liver, kidney, heart, and skin. Senescence is also part of a normal physiological response in adults. Normal megakaryocytes, natural killer (NK) cells at the interface between fetus and mother and the syncytiotrophoblast at the placenta, undergo senescence as part of their normal maturation. Senescence is essential for the correct functioning of these systems and might provide protective mechanisms later in life.

Senescence has also been described to fine-tune embryo development, promoting a correct balance between cell populations during embryo patterning as well as eliminating transient developmental structures. As an antitumoral, prorregenerative, homeostatic, and developmental mechanism, senescence shows its positive physiological sides. However, senescence is a highly complex and plastic phenotype that can exert antagonistic effects depending on the context.

For example, senescent cells contribute to persistent chronic inflammation (“inflamming”) as well as drive tumorigenesis by promoting angiogenesis and cell motility (i.e., invasion, migration, and metastasis). Furthermore, chronic senescence and a maintained senescence-associated secretory phenotype (SASP) have been shown to actively contribute to several pathological conditions such as atherosclerosis, diabetes, osteoarthritis, obesity, and neurodegenerative diseases. The list of conditions in which senescence negatively contributes to the development of the disease continues to increase, and for many conditions its role still needs to be clarified.

Cellular senescence is also one of the main hallmarks of aging. Senescent cells appear to increase in number in a variety of aged mammalian tissues either due to the accumulation of potentially deleterious mutations or due to the decline in senescence-clearing mechanisms with age. This persistence leads to local and systemic inflammation, procarcinogenic effects, and the emergence of a pernicious microenvironment that promotes further injury.

In summary, senescence is capable of exerting both detrimental and beneficial processes. This seemingly antagonistic pleiotropy might be partially explained by the fact that the interaction of the senescent cells with their microenvironment is highly dependent on the context (i.e., stress inductors, cell type, rapid vs. persistent). In general, a transient response (in which the senescent cells are rapidly cleared) promotes tissue regeneration, whereas persistent senescence can have devastating effects for the organism.

Features of Cellular Senescence: An Overview

Senescence is a highly heterogeneous response that spatially and temporally depends on the context (inductor, duration of stimulus, cell type, etc.). This heterogeneity explains the lack of a universal biomarker, forcing researchers in the field to identify several traits to asseverate the presence of senescence. Recently, the International Cell Senescence Association proposed a consensus of markers to help define this phenotype including cell-cycle arrest, macromolecular damage, deregulated metabolism, and SASP. It is important to understand that not all of these characteristics need to be present, but a combination is required to determine the presence of senescence (Fig. 1).

The hallmark of senescence is an irreversible cell-cycle withdrawal instigated by stressful insults including aberrant proliferation. Two families of cyclin-dependent kinases (CDK) inhibitors are in charge of maintaining this proliferative arrest: INK4 family (comprising p16INK4A, p15INK4B, p18INK4C, and p19ARFINK4D) and Cip/Kip family (including p27Kip1, p57Kip2, and p21WAF1/Cip1 which is regulated by p53). These factors inhibit the activity of CDKs by maintaining the retinoblastoma (RB) family members in their hypophosphorylated form, complexed to E2F family transcription factors. RB-dependent repression of E2F activity results in cell-cycle arrest, which cannot be reversed by inactivation of RB or p53. This irreversible arrest is also associated with an active blockage of apoptosis mediated by antiapoptotic BCL-2 family members.

Given that senescence is a result of stressful insults, it is not surprising that DNA damage response (DDR) markers characterize its phenotype. DDR is an evolutionary conserved pathway that senses DNA damage, amplifies its signal, and engages with the cell cycle through senescence effectors. It can be assessed by cumulative activation of the double-strand break sensor proteins γH2AX, 53BP1, CHK2, and MDC1. When the damage persists, these DDR foci become permanent generating DNA-SCARS, DNA segments with stable chromatin alterations characterized by the presence of single-stranded DNA, and lack of DNA-repair proteins (RPA, RAD51).

Senescence is also associated with chromatin changes including senescence-associated heterochromatin foci (SAHF, facultative heterochromatin domains that contribute to silencing of proliferative genes visualized as DAPI-dense foci and senescence-associated distension of satellites (SADS, where centromeres’ DNA unraveled from its compact state preceding SAHF’s formation). Other common signs of DDR in senescence include oncogene activation/loss of tumor suppressors, presence of micronuclei/nucleoplasmic bridges or nuclear buds, and loss of Lamin B1 (a component of the nuclear lamina...
which triggers both local and global modifications in chromatin methylation and correlate with SAHF and SADS.59,60 Telomere erosion (the progressive shortening of the specialized nucleoprotein structures that protect chromosome ends) has been shown to induce and stabilize senescence while contributing to a persistent DDR response.61–65 Therefore, length shortening and presence of telomere-associated foci (TAFs, where markers of DNA damage such as γH2A.X colocalize with telomeres66) are frequently used as senescence biomarkers.

Damage also impacts at the protein level where the lysosomal content increases and aggregates, forming oxidized complexes known as lipofuscin.38,67 Lipofuscin accumulation can be detected by using SAβGal,38 far-red fluorescence probes such as DDAOG,68,69 Sudan Black B (SBB) staining70, or SBB analogues such as GL13.71 Other types of protein damage include protein tyrosine phosphatases (PTPs)72,73; detected by monoclonal antibodies that recognize oxidized cysteine74 and protein carbonyl residues resulting from protein carbonylation by reactive oxygen species (ROS).75 Finally, as protein damage is not reversible, activation of the ubiquitin proteasome system73,76 and presence of PML (which act as ROS sensors77) can also be useful to assess senescence.

Senescent cells also display morphological changes becoming larger, flatter, increasing lysosomal content,78 and the cytoplasm and nucleus appear vacuolised,79,80 although this is difficult to assess and less obvious in vivo due to the architectural support of the tissue. Changes in the plasma membrane are likely representative of the lipid damage that occurs in senescent cells (such as lipid-derived aldehyde modifications81 or lipid accumulation that can be detected using immunostaining for lipid-associated proteins such as perilipin82).

Furthermore, senescent cells show an abnormal metabolic profile, and, although they remain metabolically active, display mitochondrial dysfunction with more abundant mitochondria, decreased membrane potential, increased mass, and abundance of tricarboxylic acid-cycle metabolites.83 They also have compromised ATP production and produce more ROS,84 potentiating the senescence effects.85 However, as metabolic changes are a commonality with other cellular processes, it is not a consistent marker of senescence.

Finally, senescent cells secrete a variable set of factors termed the Senescence-Associated Secretory Phenotype (SASP) responsible for the beneficial and deleterious effects of senescence within the tissue.15,86–88 The SASP comprises a highly dynamic network89 of cytokines and chemokines (CX3CL1, CXCL1/2, CXCL8, SDF1, CXCR2, CCL20), interleukins (IL1α/β, IL2, IL6, IL10, IL11, IL12), angiogenic factors and growth modulators (TGFβ, PDGF, VEGF, IGF, EGF, HGF, amphiregulin), metalloproteinases (MMP), extracellular matrix (ECM; fibronectin, collagen, laminins), and exosomes.90,91 These factors allow the

---

**Fig. 1** Hallmarks of senescence in liver disease. (A) Hallmarks of senescence, including cell-cycle arrest,11,42 DDR,55,56 protein and lipid damage, lipofuscin accumulation,37,72–75 morphological and metabolic changes,83 and production of senescence-associated secretory phenotype (SASP).15,30,90 (B) Markers of senescence in liver disease. The images represent immunohistochemistry or immunofluorescence of: P21 in primary biliary cholangitis (PBC); P16 (red) in keratin 19-positive cholangiocytes (KRT19, green) in chronic rejection; decoy receptor 2 (DCR2, green) in Krt19-positive cholangiocytes (red) in PBC; γH2A.X (red) in KRT19-positive cholangiocytes (green) in PBC; P27 in primary sclerosing cholangitis (PSC); DDAOG showing lipofuscin accumulation of mouse cholangiocytes treated with TGFβ for 24 hours. All images were taken at 20 or 40×. DAPI is shown in blue. DDR, DNA damage response.
senescent cell to communicate its compromised state, reinforcing cell-cycle arrest in an autocrine manner (therefore avoiding a potential bypass toward carcinogenesis\textsuperscript{96,97}), spreading senescence to sensitize neighboring cells to the presence of stressful stimulus, and engaging the innate immune system for clearance of senescent cells.\textsuperscript{92–94}

**Cellular Senescence in the Liver**

The liver’s roles in the metabolism of toxins and its susceptibility to infectious agents make it prone to injury. In this context, senescence may be a mechanism to contain damage and promote regeneration. Whether senescence represents a consequence of the damage, an inducer agent, or an intermediate stage of disease remains unclear; however, it is a common factor across etiologies. Here we disclose the empirical evidence of senescence in the different cell populations of the liver, with particular focus on potential markers. By doing so, we would like to provide a comprehensive view of senescence and its consequences in the context of liver homeostasis, disease, and regeneration (see \ref*{Table 1} and \ref*{Fig. 2}).

**Cholangiocytes and Cellular Senescence**

The first description of cellular senescence in bile ducts comes from Lunz and collaborators, who identified senescent cholangiocytes in early stages of chronic liver allograft rejection (CR) and obstructive cholangiopathies.\textsuperscript{95} CR in liver transplant recipients is characterized by cytological alterations in cholangiocytes and ductopenia (disappearance andobliterative arteriopathy of bile ducts) resulting in progressive jaundice, allograft dysfunction, and ultimately a second transplant. Lunz et al demonstrated that ductopenia is preceded by a period of cellular senescence (characterized by p21-positive cholangiocytes that presented shortened telomeres).\textsuperscript{95} Sasaki and colleagues described similar findings.\textsuperscript{96} and Brain et al demonstrated a positive correlation between the number of senescent cholangiocytes and an increasing grade of acute rejection, biliary anastomotic obstruction, and strictureting.\textsuperscript{97}

Furthermore, Lunz et al show that cyclosporine treatment (an immunosuppressant used at liver transplantation) induces senescence in a TGFβ-dependent manner, potentially aggravating the progression of the cholangiocellular damage rather than contributing to a successful engraftment.\textsuperscript{95} Interestingly, Demirci and colleagues showed increased TGFβ1 in macrophages localizing in close proximity to the portal tracts of liver allografts with CR,\textsuperscript{98} potentially suggesting that communications between macrophages and cholangiocytes might result in TGFβ1-dependent induction of senescence in the later population.

Senescence is present in the cholangiocytes of pediatric patients with varying etiologies,\textsuperscript{99,100} which might indicate pathological development not associated with aging. In disorders that affect cholangiocytes such as biliary atresia,\textsuperscript{99,100} senescence can be observed in hepatocytes. Conversely, in conditions that primarily affect hepatocytes (e.g., tyrosinemia and fulminant hepatitis\textsuperscript{99}), senescence can be observed in both hepatocytes and cholangiocytes, suggesting transference of senescence between liver populations although potential effects of these mechanisms have to be clarified.

Senescence has also been shown to play a critical role in the development of primary sclerosing cholangitis (PSC), an autoinflammatory disorder characterized by fibrosis, strictureting, and obliteration of bile ducts.\textsuperscript{101} Cholangiocytes in PSC show multiple senescent markers such as SAβGal, p21, p16, yH2A.X, p27, and DCR2.\textsuperscript{96,102,103}

PSC’s cholangiocytes are characterized by N-Ras-induced senescence,\textsuperscript{102} reduction of Bmi1 (a repressor of p16),\textsuperscript{104} and a complex SASP (i.e., IL1α, IL6, IL8, TGFβ chemokine ligand 1, CCL2, and PAI-1 secretion).\textsuperscript{102,103} Components of the SASP has been shown to aggravate the progression of the disease by increasing fibrosis, activating immune surveillance (attracting macrophages both in vitro\textsuperscript{105} and in vivo\textsuperscript{103}), and inducing secondary senescence in the hepatic parenchyma by means of N-Ras activation\textsuperscript{102} and TGFβ-dependent mechanisms.\textsuperscript{103} Moreover, pharmacological abrogation of these pathways inhibited senescence, highlighting the potential for new therapeutic interventions toward PSC treatment in the context of cellular senescence.\textsuperscript{102,103}

Suggested mechanisms of senescence in PSC include regulation by the transcription factor ETS1 and p300 which promotes cholangiocyte resistance to apoptosis by inducing BCL-XL expression.\textsuperscript{106,107} In fact, pharmacological inhibition of BCL-XL with the small-molecule inhibitor A1331852 selectively kills senescent cholangiocytes in the Mdr2 (Abcb4) –/– murine model of PSC,\textsuperscript{108} reducing liver fibrosis by means of a PDGF-mediated apoptotic priming of mesenchymal cells.\textsuperscript{106}

The absence of intestinal microbiota exacerbates biliary senescence in the same PSC murine model and ursodeoxycholic acid (an antioxidant metabolite produced by commensal microbiota\textsuperscript{109}) is able to abrogate senescence in vitro\textsuperscript{110} providing an interesting link between microbiota, senescence, and the progression of biliary disease.

Another potential mechanism is derived from the knock-out of secretin receptor (SR, which plays a crucial role in the regulation of biliary damage and fibrosis) in a PSC murine model, effectively reducing the levels of senescence and associated ductular reaction and fibrosis.\textsuperscript{111}

In a similar fashion, senescence is present in the bile ducts in primary biliary cholangitis (PBC), an autoimmune condition characterized by granulomatous destruction of bile ducts slowly progressing to fibrosis, cirrhosis, and liver failure.\textsuperscript{112}

PBC cholangiocytes exhibit senescence markers such as SAβGal, p16, p21, significantly shorter telomeres, and yH2A. X foci indicative of DNA damage.\textsuperscript{96,113–115} Interestingly, p21 expression in some cholangiocytes appears to be independent of p53, suggesting the presence of secondary paracrine senescence mechanisms. This cholangiocyte’s SASP might be able to modulate the microenvironment by upregulating the expression of various chemokines such as CCL2 and CX3CL1\textsuperscript{116,117} promoting the infiltration of inflammatory CX3CR1+ CD3-positive T cells\textsuperscript{117} and F4/80+ macrophages.\textsuperscript{103} Furthermore,
| Table 1  | Markers of senescence in the liver, organized per cell type |
|---------|----------------------------------------------------------|
| **Effect** | **Markers** | **References** |
| Cholangiocytes | | |
| Biliary atresia | | |
| Associated with damage | SaβGal, p53, p21, p16 | 99,100 |
| Transplantation, obstructive cholangiopathies, acute rejection | | |
| Senescence correlates with damage extension | Lipofuscin accumulation, short telomeres, p21, p16, γH2A.X | 95-97 |
| Primary biliary cirrhosis | | |
| Destruction of biliary architecture, immune surveillance activation, lack of regeneration, potential trigger, exacerbation of liver disease | SaβGal, p21, p16, p27, pRb, short telomeres, γH2A.X, DCR2, 53BP1, Bmi1 decrease, IL1α, IL3, IL6, PAI1, TGFβ, CX3CL1, CCL2 | 96,102-104 |
| Primary sclerosing cholangitis | | |
| Destruction of biliary architecture, immune surveillance activation, lack of regeneration, potential trigger, exacerbation of liver disease | SaβGal, p53, p21, p16, p27, pRb, DCR2, 53BP1, short telomeres, γH2A.X, LC3, cathepsin D, Lamp1 | 96,103,113-115 |
| Cholangiocarcinoma | | |
| Potential tumor progression through SASP | p16, EZH2 overexpression | 196 |
| Hepatocytes | | |
| Acute liver disease: paracetamol intoxication | | |
| Lack of regeneration, immune surveillance activation, secondary senescence | SaβGal, p53, p21, 53BP1, DCR2, γH2A.X | 131,132 |
| Nonalcoholic fatty liver disease (NAFLD) | | |
| Senescence correlates with severity and predicts progression of NAFLD, fibrogenesis | SaβGal, p53, p21, p38, pRb, SAMP30, 4-HNE, γH2A.X, TAF, SADS, shorter telomeres, acetylation of histones H3/H4, decreased trimethylation of histone H3 at the p21 promoter, decrease of Mcm2cyclin A and PH3, increased CDK4, SNP-related variants of CDKN1a, methylation of SLC7A11, karyomegaly, nucleoplasmic bridges, nuclear buds, micronuclei | 82,135,146,151,153-164 |
| Alcoholic liver disease | | |
| Fibrogenesis, adverse outcome, | p21, PAI-1, EGR1, miR-34a, | 135,144,145 |
| Effect                                                                 | Markers                                                                 | References       |
|-----------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| **Viral hepatitis (HBV, HCV)**                                        |                                                                         |                  |
| HCV: fibrogenesis                                                      | SABGal, p53, p21, p16, pRb, ∆Np63, Sirt1, GAS2, increase nuclear size, short telomeres | 39,134,141–143,146,149 |
| HBV: protective role by limiting viral replication, antifibrotic      |                                                                         |                  |
| **Tyrosinemia**                                                       |                                                                         |                  |
| Effect upon regenerative nodules                                       | SABGal, p53, p21, p16                                                  | 99               |
| **Genetic hemochromatosis**                                            |                                                                         |                  |
| Correlation with iron loading and fibrosis stage                       | p21                                                                     | 148              |
| **Hepatocellular carcinoma (HCC)**                                     |                                                                         |                  |
| Limits HCC development, immune surveillance activation/promotion of tumor development | p53, p21, p16, pRb, ROC1, Sirt1, PANDA,                                  | 13,92,93,193–197 |
| **Hepatic stellate cells (HSCs)**                                      |                                                                         |                  |
| Liver fibrosis                                                         |                                                                         |                  |
| HSC senescence limits fibrosis                                         | SABGal, p53, p21, p16, pRb, IL22, CCN1, α6β1, PPARG, IGF1, Substance-P/NK-1R, | 19,20,181        |
|                                                                      |                                                                         | 176–180          |
| **Lymphocytes and macrophages**                                       |                                                                         |                  |
| Lymphocytes (CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>) in chronic viral hepatitis, cirrhosis and liver transplantation, NK |                                                                         |                  |
| Fibrogenesis, immune exhaustion, viral persistence, NK (antifibrotic effect) | SABGal,p21, p27, p16, p-HP1γ, γH2A.X, telomere length, CD57, PD-1, IL2, ∆Np63-miR-181a-Sirt1 NKG2D | 149,182–185, 186 |
| **Macrophages**                                                       |                                                                         |                  |
| Secondary paracrine-senescence, lack of regenerative response, M1 shift | SABGal, p53, p21, 53BP1, DCR2, γH2A.X, IFN-c, IL6                          | 132,188          |
| **LSECs**                                                             |                                                                         |                  |
| Pseudocapillarization, microcirculatory dysfunction, perivascular fibrosis | p16, IL1, IL6                                                          | 190,191          |

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; SASP, senescence-associated secretory phenotype.
monocytes/macrophages, neutrophils, and plasma cells expressing markers of autophagy such as LC3 and PDC-E2 (pyruvate-dehydrogenase complex-E2, the immunodominant autoantigen of PBC) are found in close proximity to the damaged bile ducts in PBC. These findings highlighted a potential connection in PBC for senescence and autophagy (critical for the rapid protein remodeling required for the transition from proliferation to senescence). Indeed, PBC cholangiocytes show markers of autophagy including p62 aggregation (p62 sequestosome-1), LC3, LAMP-1, and cathepsin D. In fact, LC3 colocalizes with the mitochondrial proteins PDC-E2 and COX1. Inhibition of autophagy by means of 3-methylenedine significantly suppressed cellular senescence in cultured cells reducing the levels of CCL2 and CX3CL1.

Together these data suggest a role for senescence in the modulation of cholangiocellular damage and indicate that targeting senescence can potentially improve the conditions and the secondary symptoms associated with the progression of biliary disease. However, the mechanisms underlying these phenomena and their contribution to the onset/development of biliary disease remain unclear. Given that the K19CreERT2 Mdm2-/- mouse model (able to induce senescence exclusively in cholangiocytes) recapitulates numerous characteristics of PBC/PSC, we suggest that senescence might be an inducer rather than a consequence of biliary disease. However, the mechanisms leading to this first generation of senescence are yet not clarified.

Oxidative stress (a known inducer of cellular senescence) is characteristic of biliary pathology. The alterations in vascular supply associated with some of these conditions are an important source of oxidative stress and immune infiltrates contribute to biliary damage through the production of ROS and nitric oxide. In fact, multiple in vitro experiments demonstrated that oxidative stress consistently induces senescence in cholangiocytes. However, multiple other mechanisms including DNA damage or serum deprivation are equally capable of inducing senescence in cholangiocytes, highlighting that induction is multifactorial and likely impacts various biological processes.

Telomere shortening has also been described as an inducer of senescence in biliary disease, with short telomeres being characteristic of PBC cholangiocytes. However, given that in this study PBC and control liver samples had a similar age ratio, senescence in this context is unlikely to be related to aging, but rather could be a direct consequence of DNA damage.

Autophagy and immunological damage have also been proposed as inducers and/or contributors of cholangiocyte senescence. The SASP is certainly able to induce further damage as well as senescence in bystander cholangiocytes and other liver populations suggesting that once senescence is established it might exert further detrimental effects via a positive feedback loop.
Finally, the potential contribution of other insults (i.e., toxic bile accumulation during flow impairment, immune response, portal inflammation, and ECM deposition) to cholangiocellular senescence is worth noting. In summary, there is a complex picture for senescence in biliary pathology that requires further investigation.

**Hepatocytes and Cellular Senescence**

The hepatocyte changes with age. Hepatocytes decline in volume and the nucleus changes morphology while increasing the incidence of polyploidy. Although hepatocytes accumulate markers of senescence in later stages of life, they are not particularly susceptible to the implementation of senescence in homeostasis (probably reflecting their high regenerative and restorative capacities). However, senescent hepatocytes are common in a variety of pathologies, indicating that this might be a relevant mechanism in the context of liver disease.

Hepatocyte senescence is strongly induced in the setting of severe acute liver injury. Hepatocytes in paracetamol poisoning are characterized by the presence of SAβGal, p21, and γH2A.X, and senescence is able to spread between adjacent cells in a feedback loop dependent on macrophages’ TGFβ1 secretion. This mechanism might initially help to contain the pericentral necrosis seen in paracetamol-derived injury, as the senescent cells seem to surround the damaged areas. However, it actively contributes to the lack of regeneration seen in acute liver injury, highlighting the potential of targeting senescence and its effectors to restore the regenerative response of the liver.

Similarly, senescent hepatocytes are characteristic of chronic liver disease, a condition caused by sustained liver damage, accumulation of scarring tissue (fibrosis), and eventual progression to cirrhosis manifesting as a deterioration of liver function. In this case, the hepatocyte's telomere length inversely correlates with increasing levels of cirrhosis and mutations in telomerase genes TERT and TERC are risk factors for the development of cirrhosis. In fact, murine models in which senescence is induced in hepatocytes through a telomerase knockout show increased fibrosis, accelerated onset of cirrhosis, and reduced survival. Moreover, mice that exhibit a deficient senescent response (e.g., p21 knockout) display reduced CCl4-induced fibrosis indicating the ability of senescent cells to regulate their microenvironment through the control of ECM deposition and production of profibrotic factors.

Etiologies where presence of senescent hepatocytes have been reported include viral hepatitis B and C virus (HBV and HCV), alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), and genetic hemochromatosis.

HBV and HCV exhibit large cellular changes in hepatocytes identified as senescent lesions (with accumulation of p21, SAβGal, and SAHF with me-H3K9). In HBV, hepatocytes are found in a p21-mediated G1 arrest, showing decreased markers of late stages of cell-cycle progression, a decrease of telomere length, and an increase of nuclear size, all indicative of a strong senescent response. Interestingly, the core antigen of HBV (HBCAg) can only be observed in actively proliferating hepatocytes with intact telomere length. Moreover, p21 is associated with limitation of fibrosis and cell-cycle entry (assessed by Mcm2 expression) and correlates with increased levels of fibrosis and viral replication. These results appear to confer senescence a protective role as HBV is confined in young, proliferative hepatocytes, potentially explaining the low viral load in cirrhotic patients with a large number of senescent hepatocytes.

Senescence is characteristic of hepatocytes in HCV (with elevated expression of p21, upregulation of Trp53 and CDKN2A, SAβGal accumulation, presence of 8-OHdG [a marker of oxidative DNA damage], and a decrease of telomere length), among others. In this context, Sekoguchi et al proposed that senescence may be a consequence of an HCV-dependent hyperproliferative response that induces telomere shortening and increases fibrosis. However, Wandrer et al proposed that immune CD3+ T cells, rather than hepatocytes, are the predominant senescent population in HCV during fibrosis progression. This finding opens new avenues for the selective targeting of different liver populations by inducing host senescence to avoid viral replication or inhibiting immune senescence to contain the infection.

In ALD, the presence of senescent p21-positive hepatocytes is closely related to fibrosis development and an adverse outcome. In fact, 5 weeks of ethanol feeding in mice leads to SAβGal accumulation and upregulation of senescence initiators (PAI-1 and EGR1) in hepatocytes. Interestingly, silencing of either PAI-1 or EGR1 reduces senescence in human-cultured hepatocytes while decreasing levels of profibrotic markers, suggesting a direct link between the onset of senescence and ALD progression. Similarly, inhibition of miR-34a (which is found increased in clinical samples of ALD) decreases overall hepatocyte senescence in ethanol-fed mice while ameliorating fibrosis. Altogether these results suggest a potential role for cellular senescence as a causal event of an effector of ALD progression.

NAFLD and its histological phenotype nonalcoholic steatohepatitis (NASH) encompass a spectrum of conditions, of a broad range of etiologies, characterized by the accumulation of hepatic steatosis in patients who do not consume harmful amounts of alcohol.

NAFLD hepatocytes are characterized by the presence of multiple senescence markers including p53, SAβGal, p21, p16, p38, 4-HNE, γH2A.X, presence of TAF and SADS, as well as karyomegaly as assessed by morphometric analysis of DAPI. As with other chronic liver diseases, hepatocyte senescence correlates with severity of NAFLD. Hepatocyte in NAFLD have shorter telomeres and increased levels of CDK4, and a significant decrease of Mcm2, cyclin A, and PH3, all indicative of lack of cell-cycle progression beyond the G1/S phase. Single-nucleotide polymorphism-related variants of CDKN1A (p21), acetylation of histones H3 and H4, and decreased trimethylation of...
histone H3 at the p21 promoter \(^{152}\) directly correlate with NAFLD progression.

Further markers of senescence, such as genomic instability (assessed by nucleoplasmic bridges, nuclear buds, and micronuclei) \(^{158}\) and DNA damage, \(^{159}\) are also directly related to NAFLD progression. Furthermore, DNA methylation appears to be characteristic of NAFLD, \(^{160}\) with upregulation of genes associated with lipid metabolism and downregulation of genes related to proliferation and transcriptional regulation, \(^{161}\) methylation of SLC7A11 indicative of reduced steatotic risk, \(^{162}\) and hypomethylated genes characterizing advanced stages of NAFLD \(^{163}\) and changes in nuclear size. \(^{82,164}\)

Several senescence-related mechanisms have been causally related to NAFLD onset/progression. For example, as the CDK4-C/EBPα-p300 axis is a critical regulator of NAFLD, pharmacological inhibition of CDK4 results in cellular senescence ablation and reversion of age-dependent steatosis. \(^{156}\) The reduction of hepatic senescent protein SMP30 (regucalcin, an antioxidant protein that plays an important role in intracellular Ca\(^{2+}\) homeostasis and oxidative stress) \(^{165}\) has been associated with NAFLD progression and fibrosis in a stage-dependent manner. \(^{166}\) Consistently, SMP30 knockout mouse develops characteristics of fatty liver disease, \(^{167–169}\) suggesting a direct role for SMP30 deregulation in the development of NAFLD.

Finally, conditional induction of senescence in hepatocytes (using the Alb-Xpg \(-/-\) mice that accumulates DDR markers and accelerates karyomegaly in hepatocytes) \(^{170}\) impairs the capacity of mitochondria to oxidize fatty acids, thus accumulating fat in the hepatic parenchyma. \(^{82}\) Interestingly, elimination of senescent cells using suicide gene-mediated ablation (INK-ATTAC mice), a combination of senolytics (dasatinib + quercetin) \(^{82}\), or caloric restriction \(^{171}\) protects or even reverses hepatic lipid accumulation, \(^{82}\) suggesting new therapeutic approaches based on targeting senescence.

As with cholangiocytes’ senescence, consistent and marked oxidative injury appears to play a crucial role in the establishment of hepatocellular senescence. Oxidative stress is a common element of chronic liver disease, contributing to the onset and progression of inflammation and fibrosis. \(^{172}\) For example, patients with NAFLD show a high level of oxidative stress \(^{173,174}\) that contribute to fat accumulation, telomere shortening, and DNA damage in hepatocytes. \(^{146}\) Senescence also contributes to fat accumulation when mitochondria lose their ability to metabolize fatty acids efficiently. \(^{82}\) Therefore, either as a cause or a consequence of the pathology, senescence appears to generate a continuous feedback loop that negatively impacts the hepatocyte and its mitochondrial function. Another example: HCV core protein is able to directly induce oxidative injury and mitochondrial damage. \(^{175}\) In a similar fashion, telomere attrition and telomerase mutations appear to be predominant mechanisms for senescence induction in hepatocytes \(^{136,137}\) although telomere damage is closely associated with oxidative stress. \(^{51}\)

The hepatocyte’s role in the metabolism of endo and xenobiotics (including toxins such as alcohol) results in a constant wave of insults that may compromise their homeostatic balance toward apoptosis, regeneration, or senescence. However, given the complexity and variety of conditions that affect the hepatocytes, the mechanisms that lead to the establishment of primary senescence in this cell type need further clarification.

**Other Liver Populations and Cellular Senescence**

The role of the hepatic stellate cells (HSCs) in liver disease is intimately related to fibrogenesis, as activated HSCs secrete an excess of ECM components such as collagens and MMP that alter the architecture of the liver and compromise the function of its cells. HSC senescence reduces ECM deposition and increases the level of ECM-degrading enzymes to limit and reverse fibrogenesis. \(^{19}\) Conversely, a deficient senescent response results in exacerbated fibrosis as HSCs continue to proliferate and deposit ECM. \(^{177}\)

Multiple inducers of senescence have been described in activated HSCs including an increased sensitivity to DNA damage in comparison to quiescent HSCs. \(^{176}\) For example, upregulation of IL22 promotes HSC senescence and inhibits the expression of αSMA. \(^{177}\) Indeed, mice overexpressing IL22 have reduced levels of fibrosis. \(^{177}\)

Accumulation of matricellular protein CCN1 in hepatocytes of human cirrhotic livers induces senescence in HSCs and portal fibroblasts through ROS accumulation and an excessive production of integrin α6β1. \(^{20}\) In fact, HSC senescence was required for CCN1 to reverse hepatic fibrosis, and although CCN1 is not essential for liver function or its development, CCN1 deletion in hepatocytes results in exacerbated fibrosis concomitant with a deficient senescent response. \(^{20}\) IGF1 is also able to induce HSC senescence and limit fibrosis in a p53-dependent manner. \(^{178}\) Indeed, treatment with recombinant IGF1 limits fibrosis by promoting HSCs’ senescence via PPARγ/p53 activation. \(^{179}\) Further mechanisms of senescence activation in HSCs involve substance-P (SP)/NK-1R axis. \(^{180}\) Consistent with other studies linking HSC senescence and fibrosis, mice treated with an NK-1R inhibitor display enhanced HSCs’ senescence and a reduction in fibrogenesis. \(^{180}\)

In contrast, Yoshimoto et al reported the opposite effects with deoxycholic acid (DCA), which caused DNA damage in HSC and was shown to provoke a SASP phenotype, promoting fibrosis. \(^{181}\) Without resolution, chronic exposure to HSC-SASP promotes fibrosis and may leave patients with NASH susceptible to HCC development. In addition, HSCs appear to have longer telomeres in comparison with hepatocytes in chronic liver disease, \(^{133,146}\) potentially indicating that HSCs are less prone to establish a telomere-dependent senescent response, although the biological implications of this finding require further clarification.

To summarize, multiple studies appear to indicate that senescence in HSCs is a beneficial mechanism to avoid excessive fibrosis, although more details are required to fully understand the mechanisms that lead to this phenotype and how to manipulate them to alleviate this burden.

Other liver populations are susceptible to the implementation of cellular senescence, with variable results.
Senescence in lymphocytes has been described in chronic viral hepatitis (CD4+, CD3+, CD8+) and liver transplant recipients. This phenotype has been associated with increased fibrogenesis, immune exhaustion, and viral persistence.

NK cell receptor (NKG2D) has also been identified as a crucial factor for the regulation of immune surveillance and protection against liver fibrosis by recognizing MICA and ULBP2 in senescent-activated HSCs.

Liver-resident macrophages also participate in the senescent phenotype during paracetamol overdose by spreading senescence to bystander cells via the TGFβ1 ligand. Se- nescent HSCs also release factors such as IFN-c and IL6 that induce an M1 shift in liver-resident macrophages, promoting immune surveillance. Furthermore, given the association of autoagy and senescence and the recent description of "macroph-aging" in old mice, where senescence spreads to immune cells aggravating the pathology, we predict that the number of studies relating macrophages and senescence will increase in the coming years.

Finally, aged liver sinusoidal endothelial cells (LSECs) express high levels of p16, IL1, and IL6, concomitant to microcirculatory dysfunction and pseudocapillarization. LSECs isolated from p19ARF-/- mice are able to escape senescence in vitro without evidencing signs of tumorigene- sis and elimination of p16- LSECs disrupts the blood–tissue barriers inducing perivascular fibrosis associated with health deterioration, evidencing the importance of senescence in the maintenance of homeostasis in this cell type.

Cellular Senescence and Liver Carcinogenesis

Senescence has long been considered an antitumoral mechanism. In the liver, examples include the establishment of senescence in premalignant hepatocytes to limit cancer development, SASP-dependent recruitment of immune cells to remove senescent hepatocytes and prevent malignant transformation, and induction of senescence by means of ROC1 ablation to suppress further growth of malignant hepatocytes. Moreover, a defective senescent response is associated with the onset and progression of several liver tumors.

However, it is now clear that senescence may also trigger liver carcinogenesis. Senescence has been associated with the pathophysiology of cholangiocarcinoma by promoting tumor development. Furthermore, it has also been associated with hepatocellular carcinoma (HCC) development, where a "senescence-bypass" (product of senescence "effectors inactivation") leads to DNA damage and chromosomal instability that characterize the progression toward malignancy. Other mechanisms of HCC development include enterohemeric circulation of DCA (a secondary bile acid produced by gut bacteria). This metabolite promotes a SASP phenotype in HSC, facilitating the development of HCC.

Although these results demonstrate the importance of senescence in liver carcinogenesis, more studies are required to understand and manipulate senescence to prevent and/or treat liver cancer.

**Cellular Senescence and Mechanisms of Liver Regeneration**

The liver is an organ with exceptional regenerative properties. During homeostasis, turnover of hepatocytes is modest with < 0.5% proliferating at any given time. However, the liver is capable of completely restoring its mass from the remaining tissue after 75% resection, showing a remarkable ability to enter the cell cycle to restore liver mass.

Hepatocyte death followed by the activation of proliferative and inflammatory pathways is traditionally viewed as the main regenerative mechanism in the liver. Liver regeneration is a complex process that can dramatically differ depending on the type of injury, but commonly involves a multicellular response, restoration of the innate-immunity landscape, and revascularization of damaged areas. Within this complex process, senescence appears to play an important role in the mechanisms that determine successful or failed regeneration.

Incidence of liver disease (as well as poorer outcomes) increases with age while the regenerative capacity of the organ decreases. Accumulation of senescent hepatocytes with age decreases their regenerative rate and, as a consequence, complete restoration of liver mass after partial hepatectomy (PH) is delayed.

In PH (a well-established model of liver regeneration) there is a careful coordination between cell proliferation and cell death that defines the compensatory growth of the organ. In this setting, several studies have identified senescent markers p21 and p27 in hepatocytes, with p21 reaching maximum levels in a p53-independent fashion at 48 hours after PH. The hepatocytes of p21-deficient mice progress faster into the DNA synthesis phase, while p21 overexpression impairs hepatocyte proliferation after PH. Furthermore, secondary hepatocyte senescence (in a model in which primary senescence is induced in cholangiocytes) failed to regenerate after 48 hours of PH, suggesting that senescence controls an effective liver mass recovery.

In fact, hepatocytes in adult mouse livers subjected to PH presented high levels of p21 expression and SASP factors but lacked other senescent markers such as p16 or SAβGal. Although p21 alone may not represent a standard senescent phenotype, genetic deletion of p21 partially rescued liver regeneration. Furthermore, treatment with the senolytic drug ABT737 decreased p21 and SASP expression while improving liver regeneration, highlighting its potential for regenerative-based treatments.

Overall, these results suggest that senescence is a protective mechanism at 48 hours after PH (when the rate of DNA damage peaks alongside the increase in DNA synthesis). However, if the balance between proliferation and senescence in the remaining hepatocytes tilts toward senescence, the regenerative ability of the liver will be compromised, although senotherapeutics showed promising results as potential enhancers of regeneration.
Senescence might also be a control mechanism to prevent excessive growth beyond the point of repair, where the liver function is already restored. Similar mechanisms of developmental senescence have been described to pattern embryo structures, again in a p21-dependent and p53-independent manner.\textsuperscript{27,28}

The SASP might be partially responsible for this response, as it has been shown to induce cellular plasticity,\textsuperscript{18} activate stem cells,\textsuperscript{18} and provide signals critical for cellular reprogramming.\textsuperscript{17} A murine model of hepatocyte senescence subjected to further dietary damage shows a strong activation of biliary epithelial cells (BECs) with bioplasticity capacity to become cholangiocytes or hepatocytes and restore liver mass and function.\textsuperscript{208,209} This suggests that in a situation where senescence in the hepatic parenchyma renders this population unable to proliferate and repair the injury, the liver still retains alternative regenerative pathways based on stem cell-related mechanisms to prevent further damage, regenerate the damaged areas, and restore liver function. Further studies will define in the future if the SASP of these senescent hepatocytes includes factors that facilitate this regenerative response (\textit{\textsuperscript{2}Fig. 2}).

**Targeting Cellular Senescence: the Future of Therapeutics in Liver Disease?**

Cellular senescence is a complex phenotype and its consequences for liver homeostasis, disease, and regeneration are still under study. In the liver, senescence is a highly antagonistic pleiotropic response, dependent on a spatial/temporal context. As a protective element, short-term senescence is associated with antitumoral, hepatoprotective, antiﬁbrotic, and proregenerative mechanisms.\textsuperscript{11,15} However, it has also been linked to impaired regeneration, carcinogenesis, and progression of inﬁammation.\textsuperscript{7,11,15,31}

Cellular senescence underlies most types of chronic liver disease, where the persistence of inﬁammation and the alteration of the fine balance between regeneration and destruction might lead to the implementation of senescence. However, murine models have shown that senescence per se is able to recapitulate the onset key events of several liver conditions, suggesting a causative role for this phenomenon.\textsuperscript{103}

Either as a triggering factor or a consequence of the pathology, senescence has proven to be a relevant factor in liver disease. As so, several groups propose to use senescence markers to help establish diagnosis and severity of chronic conditions (such as p21 in CR,\textsuperscript{95} chitotriosidase in HCV,\textsuperscript{149} or SMP30 in NAFLD\textsuperscript{166}). However, the necessity of finding several factors and lack of superficial noninvasive markers complicate the use of senescence as a diagnostic tool.

Studies looking at the effects of preventing, reducing, or inducing senescence in the context of liver disease are currently under way. For example, manipulation of host senescence could block hepatitis virus infection,\textsuperscript{142} while inhibiting immune senescence could prevent the spread of hepatitis viruses.\textsuperscript{149} Induction of senescence in HSCs could reduce fibrosis,\textsuperscript{19} while blocking hepatocellular senescence might be advantageous to reverse cirrhosis\textsuperscript{131,138} and treat NAFLD.\textsuperscript{137} Blocking of SASP factors could prevent the detrimental effects of cholangiocyte senescence in PBC\textsuperscript{103} and promote liver regeneration in the setting of acute liver damage.\textsuperscript{132} Furthermore, controlling senescence-related pathways, such as autophagy or apoptosis, might be another strategy to manipulate this phenotype therapeutically.\textsuperscript{46}

In line with these findings, several groups have reported the use of novel agents able to induce senescence (curcumin,\textsuperscript{179} tetramethylpyrazine,\textsuperscript{210} retinoic acid,\textsuperscript{211} or dihydroartemisinin\textsuperscript{212} in HSCs) or eliminate senescent cells by means of senolytics (such as A-1331852,\textsuperscript{106} dasatinib + quercetin\textsuperscript{82}) to restrain the damage and induce liver regeneration. Selective elimination of senescent cells may be key to the success of senolytics as demonstrated recently in a mouse model of HCC in which therapy-induced senescent cancer cells were specifically targeted with the mTOR inhibitor AZD8055, and the survival time was almost doubled.\textsuperscript{213}

Partial blockage of SASP factors has also proven to be a useful strategy to manipulate senescence effects.\textsuperscript{103,132} Other strategies aimed at modulating senescence in other tissues might be useful for treating liver conditions, such as metformin administration,\textsuperscript{214} caloric restriction,\textsuperscript{215} or use of nanocarriers.\textsuperscript{216}

Modulation of senescence by means of senolytics, senomorphics, or SASP-blocking agents could also help us to manipulate the intrinsic regenerative abilities of the liver. By doing so we might be able to promote an endogenous BEC-dependent reparative response and improve the engraftment and proliferation of transplanted cells used in cell therapy.\textsuperscript{208}

The aging population, combined with the increasing incidence of liver disease, has sparked a new wave of interest in senescence related to hepatology. Because of the inherent complexities of the senescence process, it will be crucial to understand the mechanisms and consequences of senescence in liver disease to develop effective senescence-targeted therapies. Moreover, study of emerging fields such as epigenetics\textsuperscript{217,218} that could influence the senescence response in the liver in association with other pathologies (such as obesity\textsuperscript{219}), “macorh-aging” and its implications for immune surveillance\textsuperscript{30,220} and its associated “inflammaging”\textsuperscript{221,222} (characterized by the upregulation of the inflammatory response that occurs with advancing age), will immensely contribute to the understanding of liver disease and regeneration.

**Main Concepts and Learning Points**

- Cellular senescence plays a relevant role in the occurrence and development of liver disease.
- We provide a comprehensive list of senescence markers and related mechanisms in liver homeostasis and disease.
- We discuss the implications of cellular senescence for liver regeneration.
- Manipulation of cellular senescence as a potential therapeutic intervention.

**Funding**

This study was supported by Research Councils UK and Medical Research Council (MR/P016839/1, UKRMP, and MR/R015635/1).
Conflict of Interest

The authors declare they have no conflict of interest.

References

1. Kirkwood TB. Where will it all end? Lancet 2001;357(9256):576
2. Source: Office for National Statistics, UK. Accessed February 11, 2020 at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifecourse/latest/keyfigures/lifespanexpectancies/articles/howhaslifespanexpectancyc.changedovertime/2015-09-09
3. Kirkwood TB, Austad SN. Why do we age? Nature 2000;408(6809):233–238
4. Carrel A. On the permanent life of tissue outside of the organism. J Exp Med 1912;15(05):516–528
5. Friedman DM. The Immortalists: Charles Lindbergh, Dr. Alexis Carrel, and Their Daring Quest to Live Forever. 2nd ed. New York, NY: Harper Collins; 2008:12
6. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol 2000;1(01):72–76
7. Campisi J. Replicative senescence: an old lives’ tale? Cell 1996;84(04):497–500
8. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961;26:585–621
9. Forbes SJ, Newsome PN. Liver regeneration - mechanisms and models to clinical application. Nat Rev Gastroenterol Hepatol 2016;13(08):473–485
10. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dyeing or complementary cell fates? EMBO Rep 2014;15(11):1139–1153
11. Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path forward. Cell 2019;179(04):813–827
12. Wang Y, Xu Q, Sack L, Kang C, Elledge SJ. A gain-of-function senescence bypass screen identifies the homeobox transcription factor DLX2 as a regulator of ATM-p53 signaling. Genes Dev 2016;30(03):293–306
13. Lee S, Schmitt CA. The dynamic nature of senescence in cancer. Nat Cell Biol 2019;21(01):94–101
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(05):646–674
15. Muñoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol 2014;15(07):482–496
16. Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell 2014;31(06):722–733
17. Mosteiro L, Pantoja C, Alcazar N, et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science 2016;354(6315):1020–1030
18. Ritschka B, Storer M, Mas A, et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev 2017;31(02):172–183
19. Krizhanovsky V, Yon M, Dickins RA, et al. Senescent cell accumulation that can be induced in young mice by senescent cells. EMBO Rep 2014;15(11):1183–1190
20. Kim KH, Chen CC, Monzon RI, Lau LF. Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. Mol Cell Biol 2013;33(10):2078–2090
21. Wolstein JM, Lee DH, Michaud J, Buot V, Stefanich B, Plotkin MD. INK4a knockout mice exhibit increased fibrosis under normal conditions and in response to unilateral ureteral obstruction. Am J Physiol Renal Physiol 2010;299(06):F1486–F1495
22. Zhu F, Li Y, Zhang J, et al. Senescent cardiac fibroblast is critical for cardiac fibrosis after myocardial infarction. PLoS One 2013;8(09):e74535
23. Jun JI, Lau LF. Cellular senescence controls fibrosis in wound healing. Aging (Albany NY) 2010;2(09):627–631
24. Besancenot R, Chaligné R, Tonetti C, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol 2010;8(09):e1000476
25. Rajagopalan S, Long EO. Cellular senescence induced by CD158d reprograms natural killer cells to promote vascular remodeling. Proc Natl Acad Sci U S A 2012;109(50):20596–20601
26. Chuprin A, Gal H, Biron-Shental T, et al. Cell fusion induced by ERVWE1 or measles virus causes cellular senescence. Genes Dev 2013;27(21):2356–2366
27. Muñoz-Espin D, Cañamero M, Maraver A, et al. Programmed cell senescence during mammalian embryonic development. Cell 2013;155(05):1104–1118
28. Storer M, Mas A, Robert-Moreno A, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 2013;155(05):1119–1130
29. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014;69(Suppl 1):S54–S59
30. Hall BM, Balan V, Gleiberman AS, et al. Aging of mice is associated with p16(INK4a)- and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. Aging (Albany NY) 2016;8(07):1294–1315
31. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5(01):99–118
32. Childs BG, Baker DJ, Wijshake T, Conover CA, Campisi J, van Deursen JM. Senescent immortalized cells are deleterious at all stages of atherosclerosis. Science 2016;354(6311):472–477
33. Thompson PJ, Shah A, Ntranos V, Van Gool F, Atkinson M, Bhushan A. Targeted elimination of senescent beta cells prevents type 1 diabetes. Cell Metab 2019;29(05):1045.e10–1060.e10
34. Jeon OH, Kim C, Labeuge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med 2017;23(06):776–781
35. Palmer AK, Xu M, Zhu Y, et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell 2019;18(03):e12950
36. Bussian TJ, Aziz A, Meyer CF, Swenson BL, van Deursen JM, Baker DJ. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 2018;562(7728):578–582
37. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153(06):1194–1217
38. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92(20):9363–9367
39. Paradis V, Youssef N, Dargère D, et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol 2001;32(03):327–332
40. Melk A, Schmidt BM, Braun H, et al. Effects of donor age and cell senescence on kidney allograft survival. Am J Transplant 2009;9(01):114–123
41. Erusalimsky JD, Kurz DJ. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp Gerontol 2005;40(8-9):634–642
42. Jeyapalan JC, Ferreira M, Sedivy JM, Herbig U. Accumulation of senescent cells in mitotic tissue of aging primates. Mech Ageing Dev 2007;128(01):36–44
43. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011;192(04):547–556
44. Beauséjour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003;22(16):4212–4222
45. Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer 2015;15(07):397–410
46. Yosef R, Pihløl N, Tokarsky-Amiel R, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun 2016;7:11190
Cellular Senescence in Liver Disease and Regeneration

Georgakopoulou EA, Tsimaratou K, Evangelou K, et al. Mitochondria and cell senescence in liver disease. Seminars in Liver Disease Vol. 41 No. 1/2021 © 2021. The Author(s).

Nardella C, Clohessy JG, Alimonti A, Pandolfo M. Pro-senescence and senescence in liver disease. Seminars in Liver Disease Vol. 41 No. 1/2021 © 2021. The Author(s).

Correia-Melo C, Marques FDM, Anderson R, et al. The essence of senescence in liver disease. Seminars in Liver Disease Vol. 41 No. 1/2021 © 2021. The Author(s).

Prigione G, Perazzolo M, Passos JF, Saretzki G, Ahmed S, et al. Mitochondrial dysfunction and cell senescence in liver disease. Seminars in Liver Disease Vol. 41 No. 1/2021 © 2021. The Author(s).

Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet 2019;20(05):299–309

Swanson EC, Manning B, Zhang H, Lawrence JB. Higher-order unfolding of satellite heterochromatin is a consistent and early event in cell senescence. J Cell Biol 2013;203(06):929–942

Kuilmans J, Michaloglou C, Mooi WJ, Peepers DS. The essence of senescence. Genes Dev 2010;24(22):2463–2479

Dow Z, Ghosh K, Vizioli MG, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 2017;550(7676):402–406

Podrimaj-Bytyqi A, Borovečki A, Selimi Q, Manxhuaka-Kerflu S, Gashi G, Elezaj IR. The frequencies of micronuclei, nucleoplasmic bridges, and nuclear buds as biomarkers of genomic instability in patients with urethelial cell carcinoma. Sci Rep 2018;8(1):17873

Shimi T, Butin-Israël V, Adam SA, et al. The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev 2011;25(24):2579–2593

Freund A, Laberge RM, Demaria M, Campisi J. Lamin B1 loss is a common feature of the senescent phenotype. Nat Commun 2018;9(1):12841

Kaplon J, Zheng L, Meissl K, et al. Mitochondrial complex I deficiency promotes selective protein degradation. Genes Dev 2013;27(08):900–915

Carota JC, O’Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008;133(06):1006–1018

Kuilmans J, Peepers DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009;9(02):81–94

Hoare M, Ito Y, Kang TW, et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat Cell Biol 2016;18(09):979–992

Basisty N, Kale A, Jeon OH, et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol 2020;18(01):e3000599

Biran A, Perelmutter M, Gaal H, et al. Senescent cells communicate via intercellular protein transfer. Genes Dev 2015;29(08):791–802

Borghesani M, Fafián-Labora J, Eleftheriadou O, et al. Small extracellular vesicles are key regulators of non-cell autonomous intercellular communication in senescence via the interferon protein IFITM3. Cell Rep 2019;27(13):3956.e6–3971.e6

Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011;479(7374):547–551
Tabibian JH, O

Moncsek A, Al-Suraih MS, Trussoni CE, et al. Targeting senescent

Loarca L, De Assuncao TM, Jalan-Sakrikar N, et al. Development

Sanada Y, Kawano Y, Miki A, et al. Maternal grafts protect

Gutierrez-Reyes G, del Carmen Garcia de Leon M, Varela-Fas-

Sasaki M, Ikeda H, Yamaguchi J, Nakada S, Nakanuma Y, Telomere

Sasaki M, Ikeda H, Haga H, Manabe T, Nakanuma Y. Frequent

Lunz JG III, Contrucci S, Ruppert K, et al. Replicative senescence of

Xue W, Zender L, Miething C, et al. Senescence and tumour

for sustained tumor regression upon oncogene inactivation.

Tc e l t

fl

developmental pathways. J Biol Chem 2019;294(49):18698–18713

Xu X, Zhang J, Li K, et al. Age-related changes in liver structure and func-

tion: Implications for disease? Exp Gerontol 2005;40(8-

Strazzabosco M, Spirlí C, Okolicsanyi L. Pathophysiology of the

Young AR, Narita M, Ferreira M, et al. Autophagy mediates the

Scott M, Kukat Y, Guerra K, et al. Mitotic and replicative senescence are

Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. A possible involve-

Schmucker DL. Age-related changes in liver structure and func-

tion. Am J Pathol 2005;169(03):831–845

Loarca L, De Assuncao TM, Jalan-Sakrikar N, et al. Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary cholangiocyte senescence, and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary cholangiocyte senescence. Lab Invest 2017;97(11):1385–1396

Moncek A, Al-Suraih MS, Trussoni CE, et al. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/−) mice. Hepatology 2018;67(01):244–259

O’Hara SP, Splinter PL, Trussoni CE, et al. The transcription factor ETS5 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. J Biol Chem 2019;294(49):18698–18713

Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D, Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antiﬁ brogenic genes. J Hepatol 2005;43(06):1045–1054

Lukivskaya O, Zavodnik L, Knas M, Buko V. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv Med Sci 2006;51:54–59

Tabbian JH, O’Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 2016;63 (01):185–196

Zhou T, Wu N, Meng F, et al. Knockout of secretin receptor reduces biliary damage and liver ﬁ brosis in Mdr2−/− mice by diminishing senescence of cholangiocytes. Lab Invest 2018;98 (11):1449–1464

Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015;386(10003):1565–1575

Harada K, Furubo S, Ozaki S, Hiramatsu K, Sudo Y, Nakanuma Y. Increased expression of WAF1 in intrahepatic bile ducts in primary biliary cirrhosis relates to apoptosis. J Hepatol 2001; 34(04):500–506

Sasaki M, Ikeda H, Yamaguchi J, Nakada S, Nakanuma Y. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reﬂ ects ongoing cellular senescence. Hepatology 2008; 48(01):186–195

Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Modulation of the microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cirrhosis. J Hepatol 2010;53(02):318–325

Sasaki M, Ikeda H, Yamaguchi J, Miyakoshi M, Sato Y, Nakanuma Y. Bile ductular cells undergoing cellular senescence increase in chronic liver diseases along with ﬁ brosis progression. Am J Clin Pathol 2010;133(02):212–221

Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis. Liver Int 2013;33(02):312–320

Sasaki M, Kakuda Y, Miyakoshi M, Sato Y, Nakanuma Y. Inﬁ ltra-

Young AR, Narita M, Ferreira M, et al. Autophagy mediates the mitotic senescence transition. Genes Dev 2009;23(07):798–803

Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. A possible involve-

Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Involvement of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis. Liver Int 2013;33(02):312–320

Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Inﬁ ltration of immuno-

Schmucker DL. Age-related changes in liver structure and func-

tion. Am J Pathol 2005;169(03):831–845

Davalli P, Mitic T, Caporali A, Lauriola A, D’Arca D, ROS, cell senescence, and novel molecular mechanisms in aging and age-

related diseases. Oxid Med Cell Longev 2016;2016:3565127

Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clin Interv Aging 2018;13:757–772

Strazzabosco M, Spirili C, Okolicsanyi L. Pathophysiology of the intrahepatic biliary epithelium. J Gastroenterol Hepatol 2000;15 (03):244–253

Abe Y, Hines IN, Zibari G, et al. Mouse model of liver ischemia and reperfusion injury: method for studying reactive oxygen and nitrogen metabolites in vivo. Free Radic Biol Med 2009;46(01):1–7

Hoare M, Das T, Alexander G, Ageing, telomeres, senescence, and liver injury. J Hepatol 2010;52(05):950–961

Schmucker DL. Age-related changes in liver structure and func-

tion: Implications for disease? Exp Gerontol 2005;40(8-

Wang MJ, Chen F, Li JX, et al. Reversal of hepatocyte senescence after continuous in vivo cell proliferation. Hepatology 2014;60 (01):349–361

Verma S, Tachtatzis P, Penrhyn-Lowe S, et al. Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver. Hepatology 2012;56(04):1510–1520

Wang C, Chen WJ, Wu YF, et al. The extent of liver injury determines hepatocyte fate toward senescence or cancer. Cell Death Dis 2018;9(05):575
Cellular Senescence in Liver Disease and Regeneration

Tomita K, Teratani T, Suzuki T, et al. p53/p66Shc-mediated

Wandrer F, Han B, Liebig S, et al. Senescence mirrors the extent of hepatic cell senescence and regeneration in chronic viral hepatitis represents a senescent-related lesion. Hum Pathol 2009;40(12):1774–1782

Calado RT, Brudno J, Mehta P, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 2011;53(05):1600–1607

Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 2011;53(05):1608–1617

Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000;287(5456):1253–1258

Wiemann SU, Satyanarayana A, Buer J, Krams MP, Rudolph KL. Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage. Oncogene 2005;24(09):1501–1509

Yosef R, Pilpel N, Papismadov N, et al. p21 maintains senescent cell viability under persistent DNA damage response by restraining JNK and caspase signaling. EMBO J 2017;36(15):2280–2295

Tachtatzis PM, Marshall A, Arvinthan A, et al. Chronic hepatitis B virus infection: the relation between hepatitis B antigen expression, telomere length, senescence, inflammation and fibrosis. PLoS One 2015;10(05):e0127511

Wan Y, McDaniel K, Wu N, et al. Regulation of cellular senescence by miR-34a in alcoholic liver injury. Am J Pathol 2017;187(12):2788–2798

Meng F, Ramos-Lorenzo S, Francis H, et al. Characterization of cellular senescence mechanisms in alcoholic liver injury. FASEB J 2017;31(Suppl 1):804.3

Arvinthan AD, Alexander GJM. Senescence in chronic liver disease: Is the future in aging? J Hepatol 2016;65(04):825–834

Papathodoridi AM, Chrysavgi S, Koutsilieris M, Chatzigeorgiou A. The role of senescence in the development of nonalcoholic fatty liver disease and progression to nonalcoholic steatohepatitis. Hepatology 2020;71(01):363–374

Wood MJ, Gadd VL, Powell LW, Ramm GA, Clouston AD. Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. Hepatology 2014;59(03):848–857

Wandrer F, Han B, Liebig S, et al. Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection. Aliment Pharmacol Ther 2018;48(03):270–280

Arvinthan A, Pietrogi G, Hoare M, et al. Hepatocyte expression of the senescence marker p21 is linked to fibrosis and an adverse liver-related outcome in alcohol-related liver disease. PLoS One 2013;8(09):e72904

Tomita K, Teratani T, Suzuki T, et al. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. J Hepatol 2012;57(04):837–843

Zhang X, Zhou D, Strakovs K, Zhang Y, Pan YX. Hepatic cellular senescence pathway genes are induced through histone modi-ifications in a diet-induced obese rat model. Am J Physiol Gastrointest Liver Physiol 2012;302(05):G558–G564

Richardson MM, Jonsson JR, Powell EE, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ducular reaction. Gastroenterology 2007;133(01):80–90

Laishl, Mannasse-Green B, Hadary R, et al. Telomere dysfunction in nonalcoholic fatty liver disease and cryptogenic cirrhosis. CytoGenet Genome Res 2016;150(02):93–99

Ping F, Li ZY, Lv K, et al. Deoxyribonucleic acid telomere length shortening can predict the incidence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Diabetes Investig 2017;8(02):174–180

Nguyen P, Valanjejad L, Cast A, et al. Elimination of age-associated hepatic steatosis and correction of aging phenotype by inhibition of cdk4-C/EBPα-p300 axis. Cell Rep 2018;24(06):1597–1609

Aravinthan A, Mells G, Allison M, et al. Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcoholic-related fatty liver disease. Cell Cycle 2014;13(09):1489–1494

Karaman H, Karaman A, Donmez-Altuntas H, et al. Investigation of genome instability in patients with non-alcoholic steatohepatitis. World J Gastroenterol 2013;19(32):5295–5301

Nishida N, Yada N, Hagiwara S, Sakurai T, Kitano M, Kudo M. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016;31(09):1646–1653

Hardy T, Zeybel M, Day CP, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut 2017;66(07):1321–1328

Hotta K, Kitamoto A, Kitamoto T, et al. Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease. Sci Rep 2018;8(01):13567

Nano J, Ghanbari M, Wang W, et al. BISOS consortium. Epigenome-wide association study identifies methylation sites associated with liver enzymes and hepatic steatosis. Gastroenterology 2017;153(04):1096–1106.e2

Murphy SK, Yang H, Moylan CA, et al. Relationship between methyolme and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 2013;145(05):1076–1087

Nakajima T, Nakashima T, Okada Y, et al. Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease: comparison with telomere-specific quantitative FISH and p21 immunohistochemistry. Pathol Int 2010;60(03):175–183

Arun P, Aleti V, Parikh K, Manne V, Chilukuri N. Senescence marker protein 30 (SMP30) expression in eukaryotic cells: existence of multiple species and membrane localization. PLoS One 2011;6(02):e16545

Park H, Ishigami A, Shima T, et al. Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. J Gastroenterol 2010;45(04):426–434

Ishigami A, Fujita T, Handa S, et al. Senescence marker protein-30 knockout mouse liver is highly susceptible to tumor necrosis factor-alpha and Fas-mediated apoptosis. Am J Pathol 2002;161(04):1281–1285

Kondo Y, Hasegawa G, Okada H, et al. Lepr(db/db) Mice with systemic peroxisome proliferator-activated receptor α deficiency. PLoS Genet 2010;6(08):e1001089

Kondo Y, Masutomi H, Noda Y, et al. Senescent cells accumulate and drive hepatic steatosis and fibrosis in the absence of PPARα. Cell Rep 2015;16(08):1802–1813

Barnhoorn S, Uittenboogaard LM, Jaarsma D, et al. Cell-autonomous progeroid changes in conditional mouse models for repair endonuclease XPG deficiency. PLoS Genet 2014;10(10):e1004686
Trak-Smyrva V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol 2011;92(06):413–421

Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000;21(03):49–98

Lohr K, Pachl F, Moghadmass Ghelami A, et al. Reduced mitochondrial mass and function add to age-related susceptibility toward diet-induced fatty liver in C57BL/6J mice. Physiol Rep 2016;4(19):e12988

Kumar A, Sharma A, Duseja A, et al. Patients with nonalcoholic fatty liver disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis. J Clin Exp Hepatol 2013;3(01):12–18

Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122(02):366–375

Satyanarayana A, Greenberg RA, Schaezlein S, et al. Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol 2004;24(12):5459–5474

Kong X, Feng D, Wang H, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012;56(03):1150–1159

Nishizawa H, Iguchi G, Fukuoka H, et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. Sci Rep 2016;6:34605

Jin H, Lian N, Zhang F, et al. Activation of PPAR/β/P53 signaling is required for curcumin to induce hepatic stellate cell senescence. Cell Death Dis 2016;7:e2189

Wan Y, Meng F, Wu N, et al. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology 2017;66(02):528–541

Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell 2016;30(04):533–547

Yang D, Li L, Liu H, et al. Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. Cell Death Differ 2013;20(02):235–247

Zhu R, Mok MT, Kang W, et al. Truncated Hbx-dependent silencing of Gas2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis. J Pathol 2015;237(01):38–49

Sasaki M, Nakamura Y. New concept: cellular senescence in pathophysiology of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2016;10(05):625–638

Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007;45(04):968–976

MacDonald RA. “Lifespan” of liver cells. Autoradiographic study using tritiated thymidine in normal, cirrhotic, and partially hepatectomized rats. Arch Intern Med 1961;107:335–343

Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276(5309):60–66

Ritschka B, Knauer-Meyer T, Goncalves DS, et al. The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice. Genes Dev 2020;34(7–8):489–494

Sanz N, Diaz-Fernández C, Alvarez AM, Fernández-Simón L, Cascales M. Age-related changes on parameters of experimentally-induced liver injury and regeneration. Toxicol Appl Pharmacol 1999;154(01):40–49

Tsukamoto I, Nakata R, Kojo S. Effect of ageing on rat liver regeneration after partial hepatectomy. Biochem Mol Biol Int 1993;30(04):773–778

Fry M, Silber J, Loeb LA, Martin GM. Delayed and reduced cell replication and diminishing levels of DNA polymerase-alpha in regenerating liver of aging mice. J Cell Physiol 1984;118(03):225–232

Albrecht JH, Meyer AH, Hu MY. Regulation of cyclin-dependent kinase inhibitor p21(WAF1/Cip1/Sdi1) gene expression in hepatic regeneration. Hepatology 1997;25(03):557–563

Albrecht JH, Poon RY, Ahonen CL, Rieland BM, Deng C, Cray GS. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene 1998;16(16):2141–2150

Pujol MJ, Jaime M, Serratos J, Jaumot M, Agell N, Bach S. Differential association of p21(Cip1) and p27(Kip1) with cyclin E-CDK2 during rat liver regeneration. J Hepatol 2000;33(02):266–274

Jaime M, Pujol MJ, Serratos J, et al. The p21(Cip1) protein, a cyclin inhibitor, regulates the levels and the intracellular localization of CDC25A in mice regenerating livers. Hepatology 2002;35(05):1063–1071

Lu WY, Bird TG, Bouler L, et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nat Cell Biol 2015;17(08):971–983

Raven A, Lu WY, Man TY, et al. Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration. Nature 2017;547(7663):350–354

Jin H, Lian N, Zhang F, et al. Inhibition of YAP signaling contributes to senescence of hepatic stellate cells induced by tetramethylthylpyrazine. Eur J Pharm Sci 2017;96:323–333

Panetal C, Oben JA, Vinicultuera M, Pozienza V. Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: a putative synergy between retinoic acid and PPAR-gamma signaling. Clin Exp Med 2017;17(03):269–280
212 Zhang Z, Yao Z, Zhao S, et al. Interaction between autophagy and senescence is required for dihydroartemisinin to alleviate liver fibrosis. Cell Death Dis 2017;8(06):e2886
213 Wang C, Vegna S, Jin H, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 2019;574 (7777):268–272
214 Ovadya Y, Krizhanovsky V. Strategies targeting cellular senescence. J Clin Invest 2018;128(04):1247–1254
215 Fontana L, Nehme J, Demaria M. Caloric restriction and cellular senescence. Mech Ageing Dev 2018;176:19–23
216 Munoz-Espin D. Nanocarriers targeting senescent cells. Transl Med Aging. 2019;3:1–5
217 Sidler C, Kovalchuk O, Kovalchuk I. Epigenetic regulation of cellular senescence and aging. Front Genet 2017;8:138
218 Yang N, Sen P. The senescent cell epigenome. Aging (Albany NY) 2018;10(11):3590–3609
219 Horvath S, Erhart W, Brosch M, et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A 2014;111 (43):15538–15543
220 Prattichizzo F, Bonafè M, Olivieri F, Franceschi C. Senescence associated macrophages and “macroph-aging”: are they pieces of the same puzzle? Aging (Albany NY) 2016;8(12):3159–3160
221 Goto M. Inflammaging (inflammation + aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends 2008;2(06):218–230
222 Baylis D, Bartlett DB, Patel HP, Roberts HC. Understanding how we age: insights into inflammaging. Longev Healthspan 2013;2 (01):8